BioNTech Historical Income Statement
| BNTX Stock | USD 118.54 2.22 1.84% |
Historical analysis of BioNTech income statement accounts such as Net Interest Income of 367.2 M, Interest Income of 375.5 M or Discontinued Operations of 0.0 can show how well BioNTech SE performed in making a profits. Evaluating BioNTech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioNTech's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BioNTech SE latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioNTech SE is a good buy for the upcoming year.
BioNTech |
About BioNTech Income Statement Analysis
BioNTech SE Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioNTech shareholders. The income statement also shows BioNTech investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BioNTech Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts BioNTech SE generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of BioNTech SE minus its cost of goods sold. It is profit before BioNTech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioNTech SE. It is also known as BioNTech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from BioNTech SE operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of BioNTech SE is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in BioNTech SE financial statement analysis. It represents the amount of money remaining after all of BioNTech SE operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from BioNTech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, BioNTech's Total Other Income Expense Net is fairly stable compared to the past year. Net Income Applicable To Common Shares is likely to rise to about 12.4 B in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 5.4M | 18.9M | 7.9M | 7.5M | Depreciation And Amortization | 78.2M | 121.1M | 183.4M | 192.6M |
BioNTech income statement Correlations
Click cells to compare fundamentals
BioNTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioNTech income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | (268K) | (161M) | 4.8B | 3.5B | 255.8M | 243.0M | |
| Net Interest Income | (263K) | (3.5M) | (25.8M) | 311.4M | 349.7M | 367.2M | |
| Interest Income | 1.8M | 1.6M | 1.5M | 330.3M | 357.6M | 375.5M | |
| Depreciation And Amortization | 35.4M | 36.1M | 78.2M | 121.1M | 183.4M | 192.6M | |
| Interest Expense | 1.7M | 64.9M | 5.4M | 18.9M | 7.9M | 7.5M | |
| Selling General Administrative | 40.7M | 94.0M | 278.5M | 484.7M | 495M | 519.8M | |
| Selling And Marketing Expenses | 2.7M | 14.5M | 50.4M | 59.5M | 62.7M | 65.8M | |
| Total Revenue | 108.6M | 482.3M | 19.0B | 17.3B | 3.8B | 6.4B | |
| Gross Profit | (135.2M) | (222.0M) | 15.1B | 12.8B | 3.2B | 4.8B | |
| Other Operating Expenses | 290.1M | 564.7M | 4.1B | 4.7B | 3.1B | 2.0B | |
| Operating Income | (181.5M) | (82.4M) | 15.3B | 12.6B | 690.4M | 655.9M | |
| Net Income From Continuing Ops | (179.2M) | 15.2M | 10.3B | 9.4B | 930.3M | 883.8M | |
| Ebit | (181.5M) | (141.2M) | 14.9B | 12.3B | 904.2M | 859.0M | |
| Research Development | 226.5M | 645.0M | 102.7M | 116M | 1.8B | 1.9B | |
| Ebitda | (146.2M) | (105.1M) | 15.0B | 12.4B | 1.1B | 1.0B | |
| Cost Of Revenue | 243.8M | 704.4M | 3.9B | 4.5B | 599.8M | 569.8M | |
| Total Operating Expenses | 46.3M | (139.6M) | 200.1M | 135.9M | 2.5B | 2.7B | |
| Reconciled Depreciation | 33.9M | 38.7M | 75.2M | 123.3M | 183.4M | 192.6M | |
| Income Before Tax | (179.4M) | (145.8M) | 15.0B | 13.0B | 1.2B | 1.1B | |
| Total Other Income Expense Net | 2.1M | (63.4M) | (237.4M) | 311.4M | 495.7M | 520.5M | |
| Net Income Applicable To Common Shares | (48.0M) | (179.1M) | 15.2M | 10.3B | 11.8B | 12.4B | |
| Net Income | (179.2M) | 15.2M | 10.3B | 9.4B | 930.3M | 883.8M | |
| Income Tax Expense | (268K) | (161M) | 4.8B | 3.5B | 255.8M | 243.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.